Introduction {#sec1-2048004020940857}
============

Venous waveform analysis has recently been developed as a novel technique to accurately assess intravascular volume.^[@bibr1-2048004020940857][@bibr2-2048004020940857][@bibr3-2048004020940857][@bibr4-2048004020940857][@bibr5-2048004020940857]--[@bibr6-2048004020940857]^ The peripheral venous system is the most compliant vascular compartment of the body, and thus serves as a volume reservoir containing ∼70% of the circulating blood volume.^[@bibr7-2048004020940857]^ Because of its high compliance, the magnitude of the venous waveform is low and changes in volume are accompanied by minimal changes in pressure, rendering absolute peripheral venous pressure measurements difficult to interpret. However, studies that have analyzed harmonics of the heart rate frequency in the frequency domain of the venous waveform have revealed that the relative power contributions of the pulse rate and its harmonics change with volume and can be quantified into a value that is representative of volume status.^[@bibr1-2048004020940857][@bibr2-2048004020940857][@bibr3-2048004020940857][@bibr4-2048004020940857][@bibr5-2048004020940857]--[@bibr6-2048004020940857]^

Non-Invasive Venous waveform Analysis (NIVA) is an innovative, non-invasive method of capturing the peripheral venous waveform for analysis using a piezoelectric sensor connected to a control box ([Figure 1](#fig1-2048004020940857){ref-type="fig"}). The piezoelectric sensor is applied to the skin directly over the superficial veins of the wrist and captures small deflections in the skin that occur as a result of the pulsatile venous waveform. An early prototype device has demonstrated the ability to identify small volumes of blood loss, volume removed during hemodialysis, and correlation with a wide range of pulmonary capillary wedge pressures (PCWP), the gold-standard estimate of left ventricular preload, in patients undergoing right heart catheterization (*n* = 83, r = 0.69, *p* \< 0.05).^[@bibr1-2048004020940857][@bibr2-2048004020940857]--[@bibr3-2048004020940857]^

![Prototype NIVA device consisting of a piezoelectric sensor and control box.](10.1177_2048004020940857-fig1){#fig1-2048004020940857}

While there is growing evidence to support venous waveform analysis as a technique to monitor volume status, little is known as to how the venous waveform may be affected by vasoactive agents and whether this may confound analysis of volume status. The aim of this study was to determine the effect of vasoconstriction and vasodilation on non-invasively captured venous waveforms utilizing a porcine model.

Materials and methods {#sec2-2048004020940857}
=====================

Porcine model {#sec3-2048004020940857}
-------------

Under an approved Institutional Animal Care and Use Committee protocol, eight adult female Yorkshire pigs, 40--45 kg (Oak Hill Genetics, Ewing, IL), were intubated and ventilated with a volume-controlled ventilator (Hallowell EMC, Pittsfield, MA) at 8 mL/kg tidal volumes with oxygen FiO~2~ 1.0, a positive end-expiratory pressure of 5 cmH~2~O and I:E ratio 1:2. Respiratory rate (16--22 breaths/min) was titrated to maintain an end-tidal CO~2~ of 35--40 mmHg. General anesthesia was maintained with 1% isoflurane (Primal Healthcare, Boston, MA).

Surgical exposure of the saphenous vein in the hindlimb was obtained and a 20-mm piezoelectric sensor (ADInstruments, Colorado Springs, CO) was secured directly over the vein for continuous waveform acquisition. This direct exposure of the vein ensured that the acquired signal was purely venous and avoided attenuation of the signal from the thick porcine skin. Phenylephrine (PE) 150--180 µg IV was administered in eight pigs, followed by a 15-min equilibration period and then sodium nitroprusside (SNP) 100 µg IV in seven pigs. Additional central hemodynamic monitoring included pulmonary capillary wedge pressure (PCWP) in five pigs obtained via placement of a Swan Ganz Catheter (Edwards Lifesciences, Irvine, CA) in the right internal jugular vein, and mean arterial pressure (MAP) obtained from an arterial transducer in the left carotid artery. Hemodynamic measures were obtained within 1 min prior to and post administration of these vasoactive agents.

Venous waveform analysis {#sec4-2048004020940857}
------------------------

Venous waveforms obtained with the piezoelectric sensor were obtained at a sampling frequency of 1000 Hz and viewed in LabChart software (ADInstruments, Colorado Springs, CO). Waveforms were converted from the time to the frequency domain using a fast Fourier transform (16k windows). Two blinded study personnel independently determined and recorded peak powers of the fundamental frequency (f~0~) and its harmonics (f~1--2~) within 1 min prior to and post administration of PE or SNP ([Figure 2](#fig2-2048004020940857){ref-type="fig"}). NIVA values, which are designed to be representative of volume status, were calculated as in the previous studies using a proprietary algorithm that incorporates the relative power contributions of each cardiac frequency (f~0--2~) in relation to the total signal power.^[@bibr1-2048004020940857],[@bibr3-2048004020940857]^ This algorithm was originally developed using venous harmonics obtained from athletes before and after exercise, using a least-squares analysis to create an algorithm that correlated with insensible fluid losses quantified by changes in weight (unpublished data); the algorithm has since been validated in patients undergoing elective right heart catheterization through correlation with PCWP and absolute blood loss during mild hemorrhage.^[@bibr1-2048004020940857],[@bibr3-2048004020940857]^ Three NIVA values were derived by each independent observer from non-overlapping, low-noise segments of the venous waveform signal and averaged for analysis. From these datapoints, the ratio of the power of f~1~ to f~0~ was also calculated to more clearly elucidate morphologic changes in the waveform.

![Representative raw waveform (*top*) and fast Fourier transform (*bottom*) at (a) baseline and after (b) phenylephrine or (c) sodium nitroprusside.](10.1177_2048004020940857-fig2){#fig2-2048004020940857}

Statistical analysis {#sec5-2048004020940857}
--------------------

Statistical analyses were performed using GraphPad Prism (GraphPad Software Inc., La Jolla, CA). Comparison of NIVA values, power of f~1~ to f~0~, PCWP, and MAP prior to and post administration of PE or SNP was performed with a two-tailed paired Wilcoxon test. Means and standard error of the mean are also reported. *P*-values \<0.05 were considered significant.

Results {#sec6-2048004020940857}
=======

Phenylephrine, a vasoconstrictor, led to a significant decrease in NIVA value (9.2 ± 0.4 vs. 4.6 ± 0.6, *p* \< 0.05, [Figure 3](#fig3-2048004020940857){ref-type="fig"}) and increase in MAP (62 ± 8 vs. 87 ± 15, *p* \< 0.05, [Figure 4](#fig4-2048004020940857){ref-type="fig"}). Sodium nitroprusside, a vasodilator, resulted in a significant increase in NIVA value (9.5 ± 0.8 vs. 11.9 ± 0.6, *p* \< 0.05, [Figure 3](#fig3-2048004020940857){ref-type="fig"}) and decrease in MAP (75 ± 12 vs. 65 ± 11, *p* \< 0.05, [Figure 4](#fig4-2048004020940857){ref-type="fig"}). The ratio of the power of f~1~ to f~0~ was significantly increased with phenylephrine (0.75 ± 0.04 vs. 1.6 ± 0.3, *p* \< 0.05, [Figure 3](#fig3-2048004020940857){ref-type="fig"}) and significantly decreased with SNP (0.83 ± 0.09 vs. 0.58 ± 0.06, *p* \< 0.05, [Figure 3](#fig3-2048004020940857){ref-type="fig"}). There were no significant changes noted to PCWP with either phenylephrine (14 ± 2 vs. 16 ± 1, *p* = 0.41, [Figure 4](#fig4-2048004020940857){ref-type="fig"}) or nitroprusside (16 ± 0.7 vs. 15 ± 0.9, *p* = 0.18, [Figure 4](#fig4-2048004020940857){ref-type="fig"}).

![Changes in the ratio of the power of f~1~ to f~0~ (*top*) and NIVA value (*bottom*) after administration of (a) phenylephrine or (b) sodium nitroprusside (*n* = 7).](10.1177_2048004020940857-fig3){#fig3-2048004020940857}

![Changes in pulmonary capillary wedge pressure (PCWP, *top*, *n* = 5) and mean arterial pressure (MAP, *bottom*, *n* = 7) after administration of (a) phenylephrine or (b) sodium nitroprusside.](10.1177_2048004020940857-fig4){#fig4-2048004020940857}

Discussion {#sec7-2048004020940857}
==========

Venous waveform analysis has been described in recent literature as a promising method for estimation of intravascular volume status.^[@bibr1-2048004020940857],[@bibr3-2048004020940857][@bibr4-2048004020940857][@bibr5-2048004020940857]--[@bibr6-2048004020940857]^ In particular, non-invasive capture of peripheral venous waveforms using a piezoelectric sensor, known as NIVA, has demonstrated accuracy in identifying small volumes of blood loss as well as correlation with a wide range of pulmonary capillary wedge pressures (PCWP), an estimate of cardiac filling.^[@bibr1-2048004020940857],[@bibr3-2048004020940857]^ A better understanding of clinical variables that affect venous waveforms will help identify limitations of this technology toward volume assessment to ensure safe utilization in a patient population where vasoactive agents are administered.

Administration of vasoactive agents is common in hospital settings, and thus an understanding of the effects of vascular tone on venous waveforms has clinical relevance. This study demonstrates that administration of phenylephrine, a vasoconstrictor, or sodium nitroprusside, a vasodilator has discordant effects on the venous waveform. Administration of phenylephrine appears to dampen the power of the pulse rate frequency (f~0~) relative to the first harmonic of the pulse rate frequency (f~1~). This suggests that the fundamental frequency, or the waveform generated by the pulse rate, as detected externally is dampened after venoconstriction. It is hypothesized that the harmonics of the pulse rate are generated through reflection of the fundamental waveform from the vein wall and surrounding tissues. Therefore, the observed increase in the power of f~1~ in relation to f~0~ with venoconstriction is likely also partially explained by an accompanied decrease in compliance of the venous wall. These changes underlie the observed decrease in NIVA value, a quantitative measure used in previous studies to estimate the volume status and calculated using the relative powers of f~0-2~, with phenylephrine. Volume changes during the experiments are assumed to be minimal given the short time-frame (15--20 min). Based on these results, the NIVA value underestimated volume status in the presence of PE in this study. Sodium nitroprusside, a venodilator, led to opposite effects on the non-invasively obtained venous signal compared to phenylephrine. Namely, the relative power of f~1~ in relation to f~0~ decreased with venodilation and NIVA value increased. Thus, the NIVA value overestimated the volume status in the presence of SNP in this study.

Of note, PCWP did not change significantly with either phenylephrine or sodium nitroprusside administration; however, the sample size was small (*n* = 5) and may not have been appropriately powered to detect a difference. MAP increased with phenylephrine and decreased with nitroprusside, as would be expected with the respective increase and decrease in systemic vascular tone and resistance.

This report suggests a potential limitation for the use of NIVA, a recently described technique for static volume assessment, in patients who are actively receiving vasoactive infusions. However, additional experiments after controlled hemorrhage and volume overload will better define whether these changes persist in these settings. Further porcine experiments of controlled hemorrhage and volume overload in the setting of a continuous infusion of phenylephrine or nitroprusside may also better define whether venous waveforms can still detect dynamic volume changes in these settings. Additionally, surgical placement of the sensor directly on the vein and absence of the extravascular tissue may have had an effect on the propagation and amplitudes of the higher harmonics of the pulse rate, which may also have affected calculation of a NIVA value. However, this was chosen as the most appropriate technique due to the increased thickness of porcine skin compared to human soft tissue as well as to ensure that captured signals were purely venous. Although future experiments comparing signals from a sensor placed directly over a cutdown of the vein to a sensor placed on the skin overlying the vein may help clarify the differences in calculated NIVA values between the two techniques at various volume states, this was not deemed necessary in this report to demonstrate that fundamental signal changes are observed with altered venous tone that may affect the algorithmic calculation of a NIVA value.
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